Drugs / HRS-5765
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07551167 | May → Dec 2026 expected | heart failure | Chengdu Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-5765 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07551167 ↗ |
| Route | Oral | “Single and Multiple Oral Doses of HRS-5765” NCT07551167 ↗ |